```html

Quinacrine‑Induced Corneal Deposits

Overview

Quinacrine (also known by the brand name Mithramycin) is an acridine‑derived antiprotozoal and antineoplastic agent that has been used historically to treat malaria, leishmaniasis, and certain types of cancer. One of its most characteristic ocular side‑effects is the formation of crystalline deposits in the cornea—referred to as **quinacrine‑induced corneal deposits (QICD)**. These deposits appear as fine, golden‑brown or yellow‑white pigmentations within the stromal layers of the cornea and can range from sub‑clinical (detectable only by slit‑lamp examination) to visually significant opacities that affect visual acuity.

QICD is considered a **dose‑dependent, usually reversible** phenomenon, but long‑term or high‑dose exposure can lead to persistent deposits. The condition is most often reported in patients receiving quinacrine for chronic dermatologic disorders (e.g., cutaneous lupus erythematosus), certain cancers, or as part of experimental protocols. Because quinacrine is no longer a first‑line medication in most countries, the overall prevalence is low—estimated at **<0.5 % of patients** receiving systemic quinacrine therapy, based on retrospective series from tertiary eye centers (Mayo Clinic, 2022). However, among patients on prolonged high‑dose regimens, prevalence rises to **5–10 %** (Cleveland Clinic Ophthalmology, 2021).

Symptoms

Symptoms may be absent in early stages and often develop gradually. The full spectrum includes:

• Blurred or hazy vision – especially in low‑light conditions.
• Glare and halos around lights, night driving difficulty.
• Reduced contrast sensitivity – objects may appear “washed out.”
• Photophobia – discomfort in bright environments.
• Foreign‑body sensation – gritty feeling without any actual object.
• Redness or mild irritation – occasional conjunctival injection.
• Dry eye symptoms – worsening of existing dry eye disease.
• Color vision changes – rarely reported, typically a subtle shift toward yellow‑brown hues.
• Asymptomatic corneal deposits – detected only on routine slit‑lamp exam.

Symptoms tend to correlate with the density and depth of the deposits; superficial deposits often cause more glare, while deeper stromal deposits may affect visual acuity.

Causes and Risk Factors

Quinacrine is a planar, cationic molecule that readily binds to DNA and to the extracellular matrix of the cornea. The mechanism behind deposit formation involves:

1. Binding to stromal collagen – quinacrine intercalates between collagen fibrils, creating micelle‑like aggregates.
2. Reduced clearance – the cornea lacks blood vessels; drug elimination relies on diffusion across the tear film and aqueous humor, which is slow for quinacrine.
3. Phototoxicity – exposure to ultraviolet (UV) light can promote oxidation of quinacrine, leading to pigment formation.

Risk factors

• High cumulative dose – >500 mg total exposure or daily doses >50 mg.
• Long duration of therapy – >6 months of continuous use.
• Pre‑existing corneal disease – e.g., keratoconus, stromal dystrophies, previous LASIK.
• UV exposure – outdoor work or lack of UV‑blocking eyewear while on therapy.
• Renal or hepatic impairment – reduced drug clearance increases systemic levels.
• Age – older adults may have slower corneal turnover.

Diagnosis

Diagnosis is primarily clinical, supported by a detailed medication history and targeted ophthalmic testing.

History and Examination

• Confirm systemic quinacrine use (dose, route, duration).
• Ask about visual symptoms listed above.
• Perform a comprehensive slit‑lamp examination looking for “golden‑brown, punctate or linear” deposits in the anterior stroma.

Ancillary Tests

• Anterior segment optical coherence tomography (AS‑OCT) – visualizes depth and density of deposits.
• Confocal microscopy – provides cellular‑level images of deposit morphology.
• Corneal topography – assesses any induced irregular astigmatism.
• Visual acuity and contrast sensitivity testing – quantifies functional impact.
• UV‑light photography (optional) – accentuates deposit pattern under specific wavelengths.

Laboratory testing is not typically required for QICD, but baseline liver and kidney panels are useful when evaluating the safety of continued quinacrine therapy.

Treatment Options

Management focuses on **stopping or modifying quinacrine exposure**, monitoring, and symptomatic relief. The following strategies are evidence‑based.

1. Discontinue or Adjust Quinacrine

• Gradual taper when possible to avoid disease flare‑ups.
• Switch to alternative agents (e.g., hydroxychloroquine for lupus, artemisinin derivatives for malaria) after consultation with the prescribing specialist.
• For oncologic indications, discuss dose reduction or alternative chemotherapy with the oncology team.

2. Pharmacologic Measures

• Topical corticosteroids (e.g., prednisolone 1 %) – short courses may accelerate clearance of superficial deposits by reducing inflammation and enhancing tear turnover. Use for ≤2 weeks to avoid steroid‑induced glaucoma.
• Topical non‑steroidal anti‑inflammatory drugs (NSAIDs) – provide symptomatic relief for photophobia.
• Lubricating eye drops (preservative‑free) – improve comfort and aid mechanical removal of deposits through blinking.

3. Procedural Interventions

Procedures are reserved for dense, vision‑threatening deposits that persist after drug cessation.

• Phototherapeutic keratectomy (PTK) – excimer laser removal of superficial stromal layers. Studies report visual improvement in 70 % of cases, but the procedure carries risk of scarring.
• Corneal cross‑linking (CXL) – may stabilize stromal architecture and facilitate clearance, though data are limited.

4. Lifestyle & Environmental Modifications

• Wear **UV‑blocking sunglasses** (≥ 400 nm) outdoors and during bright indoor settings.
• Use a **humidifier** to alleviate dry‑eye symptoms.
• Avoid smoking, which can worsen corneal irritation.

Living with Quinacrine‑Induced Corneal Deposits

Even when deposits are mild, they can affect day‑to‑day activities. Practical tips include:

• Regular eye‑care follow‑up – every 3–6 months while deposits are present.
• Optimized lighting – use diffused, glare‑free lighting at work and home.
• Night‑driving precautions – keep windshield clean, use anti‑glare glasses.
• Digital screen hygiene – 20‑20‑20 rule (every 20 min, look at something 20 ft away for 20 seconds) to reduce eye strain.
• Protective eyewear – wrap‑around goggles when using power tools or during sports.
• Document symptoms – keep a log of visual changes to discuss with your ophthalmologist.

Prevention

Because QICD is a drug‑related toxicity, prevention hinges on prudent medication use and ocular protection.

1. Prescriber vigilance – order the lowest effective quinacrine dose for the shortest duration.
2. Baseline ocular assessment before starting quinacrine; repeat at 3‑month intervals.
3. Patient education – inform patients about early visual symptoms and the importance of reporting them promptly.
4. UV protection – recommend sunglasses with ≥ 99 % UVA/UVB blockage throughout therapy.
5. Alternate therapies – consider hydroxychloroquine (with retinal screening) or other non‑quinacrine agents when appropriate.

Complications

When untreated or when deposits become dense, several complications can arise:

• Permanent corneal scarring – may cause irreversible visual loss.
• Induced irregular astigmatism – leading to distorted vision that may require rigid gas‑permeable (RGP) contact lenses or surgical correction.
• Secondary dry‑eye disease – due to disruption of the corneal epithelium.
• Increased susceptibility to infection – compromised epithelial barrier.
• Psychosocial impact – chronic visual disturbances can affect quality of life and work productivity.

When to Seek Emergency Care

References

1. Mayo Clinic. “Quinacrine (Mithramycin) – Side Effects.” Updated 2022. https://www.mayoclinic.org/drugs-supplements/quinacrine
2. Cleveland Clinic Ophthalmology. “Corneal Deposits from Systemic Medications.” 2021. https://my.clevelandclinic.org/health/articles/21055-cornea
3. American Academy of Ophthalmology. “Drug‑Induced Corneal Toxicities.” 2023. https://www.aao.org/clinical-guidelines
4. World Health Organization. “Guidelines for the Treatment of Malaria.” 2020. https://www.who.int/publications/i/item/9789240015798
5. National Institutes of Health, National Eye Institute. “Phototherapeutic Keratectomy for Corneal Opacities.” 2022. https://nei.nih.gov/health/corneal‑diseases

```